Globus Medical (GMED)
NYSE:GMED
Want to see GMED full AI Analyst Report?
GMED Stock Chart & Stats
$95.25
$2.66(3.19%)
At close: 4:00 PM EST
$95.25
$2.66(3.19%)
Day’s Range― - ―
52-Week Range$51.79 - $101.40
Previous CloseN/A
Volume442.39K
Average Volume (3M)1.80M
Market Cap
$10.62B
Enterprise Value$10.60B
Total Cash (Recent Filing)$629.85M
Total Debt (Recent Filing)$115.22M
Price to Earnings (P/E)18.1
Beta0.71
Next Earnings
Jul 30, 2026EPS Estimate
1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.35
Shares Outstanding113,236,100
10 Day Avg. Volume1,771,608
30 Day Avg. Volume1,796,600
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.58
Price to Sales (P/S)4.02
P/FCF Ratio20.04
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue3.42
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda11.96
Forecast
1Y Price Target
$112.88Price Target Upside18.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)4.72
Revenue Forecast (FY)$3.20B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & Conservative Balance SheetRobust operating and free cash flow combined with minimal leverage provide durable financial flexibility. This supports ongoing R&D, capex, share repurchases, and selective M&A while insulating the business from cyclical volume dips and enabling multi‑year investment in product platforms and go‑to‑market expansion.
Margin Expansion And Upgraded EPS GuidanceManagement’s margin improvement and higher EPS guidance reflect structural operating leverage from scale, synergy capture, and mix improvement. Sustained higher gross and EBITDA margins enhance cash conversion and fund reinvestment, making profitability gains durable if management sustains execution and targeted mid‑70s gross margins longer term.
Broad-based Organic Growth And Market Share GainsConsistent organic growth across legacy spine, international, and trauma indicates durable demand and expanding share. Multi‑segment strength reduces concentration risk and supports cross‑sell (robotics, enabling tech), underpinning a sustainable revenue base and predictable scaling of margins over the medium term.
Bears Say
Nevro Integration Driving Revenue LumpinessThe acquired Nevro business is causing uneven top‑line patterns and complicating forecasting. Structural sales reorganization and right‑sizing can depress near‑term revenue and obscure underlying organic trends, making quarter‑to‑quarter performance and resource allocation less predictable over the next several months.
Elevated SG&A From Nevro IntegrationHigh integration‑related SG&A increases expense intensity and tempers operating leverage. Until synergies and cost rationalization materialize, elevated SG&A will constrain margin sustainability and free cash flow conversion, pressuring near‑term profitability despite underlying revenue growth.
Enabling Technologies Shifting To Leases/rentalsA structural move from outright sales to leasing alters revenue recognition and delays cash collection, muting near‑term top‑line growth even as long‑term recurring revenue improves. This changes cash flow timing, lengthens payback on capital equipment, and may raise working capital needs during the transition period.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $51.79 and its highest was $101.40 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $10.62B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Jul 30, 2026 which is in 51 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on May 07, 2026. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.2.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 1.1.
How many shares outstanding does Globus Medical have?
Globus Medical has 113,236,100 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $1.12 in its last earnings report, beating expectations of $0.92. Following the earnings report the stock price went down -8.37%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in GMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Globus Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.88 (18.50% Upside)
$112.88 (18.50% Upside)
Blogger Sentiment
Bullish
GMED Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 123.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
34.34%
12-Months-Change
Fundamentals
Return on Equity
13.04%
Trailing 12-Months
Asset Growth
15.46%
Trailing 12-Months
Company Description
Globus Medical
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
GMED Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, meaningful margin expansion, record non-GAAP EPS, robust cash generation, international and trauma momentum, regulatory wins for patient-specific implants, and upgraded full-year EPS guidance — all indicating solid operational execution and profitable scaling. Primary negatives centered on the Nevro integration (revenue lumpiness and elevated SG&A), a shift in enabling tech deal structures toward leases/rentals that can depress near-term revenue recognition, and some competitive/longer sales cycles in robotics. Overall, the positive performance and durable margin improvements materially outweigh the integration and mix headwinds, while management provided clear plans and targets (mid-70s gross margin long term) that support an optimistic outlook.View all GMED earnings summariesGMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
$112.88
▲(18.50% Upside)
Technical Analysis
Boston Scientific
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.73% Insiders
30.17% Mutual Funds
29.49% Other Institutional Investors
16.61% Public Companies and Individual Investors